Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Myriad Genetics's share price for the quarter that ended in Dec. 2023 was $19.14. Myriad Genetics's Shares Outstanding (EOP) for the quarter that ended in Dec. 2023 was 89.9 Mil. Therefore, Myriad Genetics's market cap for the quarter that ended in Dec. 2023 was $1,720.7 Mil.
Myriad Genetics's quarterly market cap
declined
from Jun. 2023 ($1,898.4 Mil) to Sep. 2023 ($1,316.3 Mil) but then
increased
from Sep. 2023 ($1,316.3 Mil) to Dec. 2023 ($1,720.7 Mil).
Myriad Genetics's annual market cap
declined
from Dec. 2021 ($2,208.0 Mil) to Dec. 2022 ($1,178.2 Mil) but then
increased
from Dec. 2022 ($1,178.2 Mil) to Dec. 2023 ($1,720.7 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Myriad Genetics's Enterprise Value for Today is $1,696.8 Mil.
Myriad Genetics Market Cap Historical Data
The historical data trend for Myriad Genetics's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Myriad Genetics's Market Cap
For the Diagnostics & Research subindustry, Myriad Genetics's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Myriad Genetics's Market Cap Distribution in the Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Myriad Genetics's Market Cap distribution charts can be found below:
* The bar in red indicates where Myriad Genetics's Market Cap falls into.
Myriad Genetics Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Myriad Genetics's Market Cap for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Myriad Genetics (NAS:MYGN) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Myriad Genetics Market Cap Related Terms
Thank you for viewing the detailed overview of Myriad Genetics's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.
Myriad Genetics (Myriad Genetics) Business Description
Myriad Genetics is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel with the capability to identify the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm offers biomarker discovery and companion diagnostic services to pharma and biotech companies.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
MYGN has been successfully added to your 